文献速递核素与放射性配体治疗肿瘤 PET/CT

肽受体放射性核素治疗后的治疗后显像对患者管理的影响

The Impact of Posttreatment Imaging in Peptide Receptor Radionuclide Therapy.
PubMed 文献 · J Nucl Med · 2024-03-01

本回顾性研究纳入100例接受肽受体放射性核素治疗(PRRT)的晚期高分化神经内分泌肿瘤患者,评估治疗后24小时SPECT/CT定性显像对管理的影响。27%的患者出现管理改变,其中78%为重大改变;更高肿瘤分级与管理改变率升高相关(P=0.006)。

要点

  • PRRT治疗后24小时SPECT/CT定性显像使27%患者的管理发生改变,其中78%为重大改变。
  • 多数管理改变发生在第2周期和第3周期之后。
  • 肿瘤分级越高,管理改变率越高(P=0.006)。

核心结论

  • 在这项回顾性研究中,治疗后SPECT/CT显像的定性分析为27%的患者管理改变提供了依据。
  • 肿瘤分级越高的患者管理改变率越高,且多数管理改变发生在第2周期和第3周期之后。
  • 将治疗后显像纳入标准PRRT工作流程可能有助于改善患者管理。

研究设计与样本

  • 回顾性研究,评估100例接受PRRT的晚期高分化神经内分泌肿瘤患者,均在治疗后24小时行SPECT/CT显像。

主要发现

  • 在100例连续患者中,多数患者(第2周期后80%、第3周期后79%、第4周期后73%)在PRRT期间定性评估为疾病稳定。
  • 27%(n=27)的患者出现管理改变,其中78%(n=21)为重大改变,30%(n=9)为轻微改变。
  • 多数治疗改变发生在第2周期后(重大33%、轻微67%)和第3周期后(重大62%、轻微33%)。
  • 肿瘤分级越高与管理改变率增加相关(P=0.006)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Posttreatment imaging of γ-emissions after peptide receptor radionuclide therapy (PRRT) can be used to perform quantitative dosimetry as well as assessment response using qualitative measures. We aimed to assess the impact of qualitative posttreatment imaging on the management of patients undergoing PRRT. Methods: In this retrospective study, we evaluated 100 patients with advanced well-differentiated neuroendocrine tumors undergoing PRRT, who had posttreatment SPECT/CT imaging at 24 h. First, we evaluated the qualitative assessment of response at each cycle. Then using a chart review, we determined the impact on management from the posttreatment imaging. The changes in management were categorized as major or minor, and the cycles at which these changes occurred were noted. Additionally, tumor grade was also evaluated. Results: Of the 100 sequential patients reviewed, most (80% after cycle 2, 79% after cycle 3, and 73% after cycle 4) showed qualitatively stable disease during PRRT. Management changes were observed in 27% (n = 27) of patients; 78% of those (n = 21) were major, and 30% (n = 9) were minor. Most treatment changes occurred after cycle 2 (33% major, 67% minor) and cycle 3 (62% major, 33% minor). Higher tumor grade correlated with increased rate of changes in management (P = 0.006). Conclusion: In this retrospective study, qualitative analysis of posttreatment SPECT/CT imaging informed changes in management in 27% of patients. Patients with higher-grade tumors had a higher rate of change in management, and most of the management changes occurred after cycles 2 and 3. Incorporating posttreatment imaging into standard PRRT workflows could potentially enhance patient management.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Yadav S, Lawhn-Heath C, Paciorek A, et al. The Impact of Posttreatment Imaging in Peptide Receptor Radionuclide Therapy. J Nucl Med. 2024. PMID: 38428966. doi:10.2967/jnumed.123.266614

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。